Upton G V
Medical College of Pennsylvania, Philadelphia.
Int J Fertil. 1986;30(4):44-52.
There is a growing awareness that many women over 40 require both contraceptive protection and hormonal replacement for the symptoms of the climacteric. These women are still menstruating and the risk of pregnancy remains, overshadowed by the increased life-threatening risk due to childbirth in this age group. The risk of mortality due to the use of oral contraceptives is little increased for the nonsmoking woman in the over 40 years compared with the years under 40. In contrast, women over 40 who smoke are best advised not to use hormonal contraceptives. It is evident from all the existing data that combination therapy is strongly advised if any replacement therapy is to be given a woman. There is considerable evidence suggesting that estrogen alone may be insufficient therapy and progestogen should be added to prevent endometrial hyperplasia, decrease the risk of breast cancer and prevent bone loss. In the premenopausal woman, such therapy should also provide contraception. Many physicians allow women 35 to 45 who do not smoke to continue on an oral contraceptive if there is no contraindication. However, a minimum-dose product has yet to be found close to the ideal of fulfilling both the contraceptive and therapeutic needs of women traversing a physiologically very hazardous period.
人们越来越意识到,许多40岁以上的女性既需要避孕保护,又需要激素替代疗法来缓解更年期症状。这些女性仍在月经,怀孕风险依然存在,而这个年龄组因分娩导致的危及生命的风险增加,使得怀孕风险相形见绌。与40岁以下的非吸烟女性相比,40岁以上的非吸烟女性使用口服避孕药导致的死亡风险几乎没有增加。相比之下,强烈建议40岁以上吸烟的女性不要使用激素避孕药。从所有现有数据来看,如果要给女性进行任何替代疗法,强烈建议采用联合治疗。有大量证据表明,单独使用雌激素可能治疗不足,应添加孕激素以预防子宫内膜增生、降低乳腺癌风险并预防骨质流失。对于绝经前女性,这种疗法还应提供避孕作用。如果没有禁忌证,许多医生允许35至45岁不吸烟的女性继续服用口服避孕药。然而,尚未找到接近理想状态的最低剂量产品,这种产品既能满足处于生理上非常危险时期的女性的避孕需求,又能满足其治疗需求。